Development of Non-Erythropoietic Erythropoietin Variants for Neuroprotection


Dateien zu dieser Ressource

Prüfsumme: MD5:6b24bdb20872937c639dfad4df24981a

TORUP, Lars, Marcel LEIST, 2006. Development of Non-Erythropoietic Erythropoietin Variants for Neuroprotection. In: HÖKE, Ahmet, ed.. Erythropoietin and the Nervous System. Berlin:Springer, pp. 1-9

@incollection{Torup2006Devel-7441, title={Development of Non-Erythropoietic Erythropoietin Variants for Neuroprotection}, year={2006}, address={Berlin}, publisher={Springer}, booktitle={Erythropoietin and the Nervous System}, pages={1--9}, editor={Höke, Ahmet}, author={Torup, Lars and Leist, Marcel} }

<rdf:RDF xmlns:rdf="" xmlns:bibo="" xmlns:dc="" xmlns:dcterms="" xmlns:xsd="" > <rdf:Description rdf:about=""> <dc:creator>Leist, Marcel</dc:creator> <dc:creator>Torup, Lars</dc:creator> <dc:date rdf:datatype="">2011-03-24T17:34:27Z</dc:date> <dc:contributor>Torup, Lars</dc:contributor> <dcterms:bibliographicCitation>First publ. in: Erythropoietin and the Nervous System / Ahmet Höke (ed.). Berlin: Springer, 2006, pp. 1-9</dcterms:bibliographicCitation> <dcterms:issued>2006</dcterms:issued> <dcterms:rights rdf:resource=""/> <dcterms:abstract xml:lang="eng">Erythropoietin is well known to possess erythropoietic activity, but also tissue protection. Here, we present examples on how to separate these two activities. One possibility is to generate a short-lived variant by removal of EPO s sialic acid residues. Although asialo-EPO has a high affinity for the classical EPO-R, it lacks hematopoetic activity in vivo upon bolus injection, because of its short plasma half-life. Another approach we followed was to generate carbamylated EPO (CEPO), which has no affinity for the EPO receptor, but the same neuroprotective potency as EPO. Our data suggest that the cytoprotective signal transduction of EPO is distinct from the hematopoietic signaling machinery.</dcterms:abstract> <dc:language>eng</dc:language> <dcterms:title>Development of Non-Erythropoietic Erythropoietin Variants for Neuroprotection</dcterms:title> <dcterms:available rdf:datatype="">2011-03-24T17:34:27Z</dcterms:available> <bibo:uri rdf:resource=""/> <dc:contributor>Leist, Marcel</dc:contributor> <dc:rights>deposit-license</dc:rights> <dc:format>application/pdf</dc:format> </rdf:Description> </rdf:RDF>

Dateiabrufe seit 01.10.2014 (Informationen über die Zugriffsstatistik)

Hoke_Chapter_13_final.pdf 172

Das Dokument erscheint in:

KOPS Suche


Mein Benutzerkonto